| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Providing a diverse range of perspectives from bullish to bearish, 21 analysts have published ratings on Boston Scientific (NYSE:BSX) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 12 | 8 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 3 | 0 | 0 | 0 | 0 |
| 2M Ago | 6 | 6 | 1 | 0 | 0 |
| 3M Ago | 2 | 2 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $82.81, along with a high estimate of $95.00 and a low estimate of $72.00. This upward trend is evident, with the current average reflecting a 10.93% increase from the previous average price target of $74.65.
The standing of Boston Scientific among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mike Matson | Needham | Maintains | Buy | $82.00 | $82.00 |
| David Roman | Goldman Sachs | Announces | Buy | $90.00 | - |
| John Eade | Argus Research | Raises | Buy | $95.00 | $80.00 |
| Joanne Wuensch | Citigroup | Raises | Buy | $87.00 | $85.00 |
| Anthony Petrone | Mizuho | Raises | Buy | $90.00 | $85.00 |
| Matt Miksic | Barclays | Raises | Overweight | $78.00 | $70.00 |
| Joanne Wuensch | Citigroup | Raises | Buy | $85.00 | $79.00 |
| Pito Chickering | Deutsche Bank | Raises | Hold | $73.00 | $63.00 |
| Robbie Marcus | JP Morgan | Raises | Overweight | $82.00 | $72.00 |
| Jayson Bedford | Raymond James | Raises | Strong Buy | $85.00 | $73.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $82.00 | $78.00 |
| Anthony Petrone | Mizuho | Raises | Buy | $85.00 | $80.00 |
| Danielle Antalffy | UBS | Raises | Buy | $90.00 | $74.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $82.00 | $72.00 |
| Vijay Kumar | Evercore ISI Group | Raises | Outperform | $78.00 | $72.00 |
| David Rescott | Baird | Raises | Outperform | $84.00 | $79.00 |
| Mike Matson | Needham | Raises | Buy | $82.00 | $71.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $78.00 | $70.00 |
| Vijay Kumar | Evercore ISI Group | Raises | Outperform | $72.00 | $68.00 |
| John Eade | Argus Research | Raises | Buy | $80.00 | $69.00 |
| Joanne Wuensch | Citigroup | Raises | Buy | $79.00 | $71.00 |
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Boston Scientific's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Boston Scientific analyst ratings.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Boston Scientific showcased positive performance, achieving a revenue growth rate of 13.78% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 12.84%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.53%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.38%, the company showcases effective utilization of assets.
Debt Management: Boston Scientific's debt-to-equity ratio is below the industry average. With a ratio of 0.55, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: BSX
